Apogee Therapeutics, Inc. 03770N101 US03770N1019 06/09/2026 Election of Director: Mark C. McKenna DIRECTOR ELECTIONS ISSUER 583591 0 FOR583591FOR 0 Apogee Therapeutics, Inc. 03770N101 US03770N1019 06/09/2026 Election of Director: Jennifer Fox DIRECTOR ELECTIONS ISSUER 583591 0 FOR583591FOR 0 Apogee Therapeutics, Inc. 03770N101 US03770N1019 06/09/2026 Election of Director: William (BJ) Jones, Jr. DIRECTOR ELECTIONS ISSUER 583591 0 FOR583591FOR 0 Apogee Therapeutics, Inc. 03770N101 US03770N1019 06/09/2026 Ratification of Ernst & Young LLP as independent auditor AUDIT-RELATED ISSUER 583591 0 FOR583591FOR 0 Apogee Therapeutics, Inc. 03770N101 US03770N1019 06/09/2026 Compensation of named executive officers COMPENSATION ISSUER 583591 0 FOR583591FOR 0 Spyre Therapeutics Inc. 00773J202 US00773J2024 05/27/2026 Election of Director: Mark McKenna DIRECTOR ELECTIONS ISSUER 1456231 0 FOR1456231FOR 0 Spyre Therapeutics Inc. 00773J202 US00773J2024 05/27/2026 Election of Director: Cameron Turtle, D.Phil. DIRECTOR ELECTIONS ISSUER 1456231 0 FOR1456231FOR 0 Spyre Therapeutics Inc. 00773J202 US00773J2024 05/27/2026 Election of Director: Laurie Stelzer DIRECTOR ELECTIONS ISSUER 1456231 0 FOR1456231FOR 0 Spyre Therapeutics Inc. 00773J202 US00773J2024 05/27/2026 Compensation of named executive officers COMPENSATION ISSUER 1456231 0 FOR1456231FOR 0 Spyre Therapeutics Inc. 00773J202 US00773J2024 05/27/2026 Ratification of KPMG LLP as independent auditor AUDIT-RELATED ISSUER 1456231 0 FOR1456231FOR 0 Spyre Therapeutics Inc. 00773J202 US00773J2024 05/27/2026 Amended and restated employee stock purchase plan CAPITAL STRUCTURE ISSUER 1456231 0 FOR1456231FOR 0 Oruka Therapeutics, Inc. 687604108 US6876041087 06/02/2026 Election of Director: Lawrence Klein DIRECTOR ELECTIONS ISSUER 1565661 0 FOR1565661FOR 0 Oruka Therapeutics, Inc. 687604108 US6876041087 06/02/2026 Election of Director: Chris Martin DIRECTOR ELECTIONS ISSUER 1565661 0 FOR1565661FOR 0 Oruka Therapeutics, Inc. 687604108 US6876041087 06/02/2026 Ratification of PricewaterhouseCoopers LLP as independent auditor AUDIT-RELATED ISSUER 1565661 0 FOR1565661FOR 0 Oruka Therapeutics, Inc. 687604108 US6876041087 06/02/2026 Compensation of named executive officers COMPENSATION ISSUER 1565661 0 FOR1565661FOR 0 Jade Biosciences, Inc. 008064206 US0080642061 06/09/2026 Election of Director: Christopher Cain, Ph.D. DIRECTOR ELECTIONS ISSUER 1577750 0 FOR1577750FOR 0 Jade Biosciences, Inc. 008064206 US0080642061 06/09/2026 Election of Director: Tom Frohlich DIRECTOR ELECTIONS ISSUER 1577750 0 FOR1577750FOR 0 Jade Biosciences, Inc. 008064206 US0080642061 06/09/2026 Ratification of PricewaterhouseCoopers LLP as independent auditor AUDIT-RELATED ISSUER 1577750 0 FOR1577750FOR 0 Jade Biosciences, Inc. 008064206 US0080642061 06/09/2026 To approve an amendment to Articles of Incorporation to waive jury trials in certain circumstances CORPORATE GOVERNANCE ISSUER 1577750 0 FOR1577750FOR 0 Crescent Biopharma, Inc. G2545C104 KYG2545C1042 06/02/2026 Election of Director: Susan Moran DIRECTOR ELECTIONS ISSUER 0 0 0 Proxy materials were not received; no vote was cast Crescent Biopharma, Inc. G2545C104 KYG2545C1042 06/02/2026 Ratification of PricewaterhouseCoopers LLP as independent auditor AUDIT-RELATED ISSUER 0 0 0 Proxy materials were not received; no vote was cast Crescent Biopharma, Inc. G2545C104 KYG2545C1042 06/02/2026 Compensation of named executive officers COMPENSATION ISSUER 0 0 0 Proxy materials were not received; no vote was cast Crescent Biopharma, Inc. G2545C104 KYG2545C1042 06/02/2026 To conduct an advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 Proxy materials were not received; no vote was cast Damora Therapeutics, Inc. 36322Q206 US36322Q2066 06/17/2026 Election of Director: Michael Landsittel DIRECTOR ELECTIONS ISSUER 2045473 0 FOR2045473FOR 0 Damora Therapeutics, Inc. 36322Q206 US36322Q2066 06/17/2026 Election of Director: Cameron Turtle, D.Phil. DIRECTOR ELECTIONS ISSUER 2045473 0 FOR2045473FOR 0 Damora Therapeutics, Inc. 36322Q206 US36322Q2066 06/17/2026 Compensation of named executive officers COMPENSATION ISSUER 2045473 0 FOR2045473FOR 0 Damora Therapeutics, Inc. 36322Q206 US36322Q2066 06/17/2026 To conduct an advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2045473 0 1 YEAR2045473AGAINST 0 Damora Therapeutics, Inc. 36322Q206 US36322Q2066 06/17/2026 Ratification of Ernst & Young LLP as independent auditor AUDIT-RELATED ISSUER 2045473 0 FOR2045473FOR 0